C Borg
Overview
Explore the profile of C Borg including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
52
Citations
816
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Conroy T, Gourgou S, Borg C
Ann Oncol
. 2024 Oct;
36(2):216-218.
PMID: 39401548
No abstract available.
2.
Conroy T, Castan F, Etienne P, Rio E, Mesgouez-Nebout N, Evesque L, et al.
Ann Oncol
. 2024 Jul;
35(10):873-881.
PMID: 38986769
Background: The standard of care for the treatment of locally advanced rectal cancer (LARC) results in an excellent local disease control but the metastasis rates remain high. PRODIGE 23 demonstrated...
3.
Orillard E, Spehner L, Mansi L, Bouard A, Falcoz A, Lepiller Q, et al.
Front Immunol
. 2023 Jun;
14:1160664.
PMID: 37334387
Purpose: Cancer patients are at risk of severe COVID-19 infection, and vaccination is recommended. Nevertheless, we observe a failure of COVID-19 vaccines in this vulnerable population. We hypothesize that senescent...
4.
Van Cutsem E, Danielewicz I, Saunders M, Pfeiffer P, Argiles G, Borg C, et al.
Br J Cancer
. 2022 Apr;
126(11):1548-1554.
PMID: 35440667
Background: Therapeutic options are limited in patients with unresectable metastatic colorectal cancer (mCRC) ineligible for intensive chemotherapy. The use of trifluridine/tipiracil plus bevacizumab (TT-B) in this setting was evaluated in...
5.
6.
Pages F, Andre T, Taieb J, Vernerey D, Henriques J, Borg C, et al.
Ann Oncol
. 2020 Jul;
31(9):1276.
PMID: 32653357
No abstract available.
7.
Van Cutsem E, Danielewicz I, Saunders M, Pfeiffer P, Argiles G, Borg C, et al.
Ann Oncol
. 2020 Jun;
31(9):1160-1168.
PMID: 32497736
Background: We designed an open-label, noncomparative phase II study to assess the safety and efficacy of first-line treatment with trifluridine/tipiracil plus bevacizumab (TT-B) and capecitabine plus bevacizumab (C-B) in untreated...
8.
Echalier A, Borg C, Creach C, Laurent B, Michael G
Brain Cogn
. 2020 May;
142:105568.
PMID: 32408059
Distortions of body representation have been reported in Complex Regional Pain Syndrome (CRPS). The perception of sensations arising without external triggers (spontaneous sensations or SPS) was assessed here as a...
9.
Pages F, Andre T, Taieb J, Vernerey D, Henriques J, Borg C, et al.
Ann Oncol
. 2020 Apr;
31(7):921-929.
PMID: 32294529
Background: The Immunoscore (IS), which prognostically classifies stage I-III colon cancer (CC) patients, was evaluated in the International Duration Evaluation of Adjuvant Therapy (IDEA) France cohort study investigating 3 versus...
10.
Lakkis Z, Vernerey D, Mege D, Faucheron J, Panis Y, Tuech J, et al.
Br J Surg
. 2019 May;
106(8):1087-1098.
PMID: 31074509
Background: Specific surgical and oncological outcomes in patients with rectal cancer surgery after a previous diagnosis of prostate cancer have not been well described. The aim of this study was...